Market Research Report
Therapeutic Botulinum Toxin | MedTech 360 | Market Analysis | Global | 2019
|Published by||Millennium Research Group - DRG||Product code||76548|
Delivery time: 1-2 business days
|Therapeutic Botulinum Toxin | MedTech 360 | Market Analysis | Global | 2019|
|Published: November 30, 2018||Content info:||
The global therapeutic BTX market will grow strongly through 2027, with newly approved indications, the need for repeat BTX treatments, and a largely favorable reimbursement environment driving significant procedure volume and unit sales expansion.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for therapeutic BTX in the US, France, Germany, Italy, Spain, the UK, Japan and Australia across a 10-year period.
Which indications contribute the most to growth?
What regional differences exist regarding indication approvals?
What new indications have the largest market potential?
What are some key competitive strategies being employed to succeed in the market?
How do the competitive landscapes differ by region, and what considerations must companies make in particular markets?
What key drivers contribute to a market's relative size and growth?
What factors most significantly affect pricing within markets?
Will emerging products expand on or compete against the existing BTX market?
What are some potential competitive advantages emerging products might have?
How will alternative treatments impact the BTX market?
Author(s): Robert Cohen, BSc
Robert is an analyst within the Endoscopy and Aesthetics Medtech Insights team at Decision Resources Group, specializing in the fields of aesthetic injectables and cosmetic threads. Robert holds an Honors Bachelor's degree in Immunology from McGill University.